There were, however, increased proportions of tumor-infiltrating non-T, non-NK CD11b+ immune cells expressing PD-L1 (p<0.01) in LLC tumor-bearing mice treated with RT+L19–IL2 (55.0%±11.2), as compared with RT (30.0%±10.1) (figure 5D). This evidence concerns the gene IL2 and neoplasm.